A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma

Hiroyuki Kanzaki, Fumiaki Shinohara, Maiko Suzuki, Satoshi Wada, Yutaka Miyamoto, Yuuki Yamaguchi, Yuta Katsumata, Seicho Makihira, Toshi Kawai, Martin A. Taubman, Yoshiki Nakamura

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Interferon-gamma (IFN-Î 3) is a pleiotropic cytokine that exerts anti-tumor and anti-osteoclastogenic effects. Although transcriptional and post-transcriptional regulation of IFN-Î 3 is well understood, subsequent modifications of secreted IFN-Î 3 are not fully elucidated. Previous research indicates that some cancer cells escape immune surveillance and metastasize into bone tissue by inducing osteoclastic bone resorption. Peptidases of the a-disintegrin and metalloproteinase (ADAM) family are implicated in cancer cell proliferation and tumor progression. We hypothesized that the ADAM enzymes expressed by cancer cells degrades IFN-Î 3 and attenuates IFN-Î 3-mediated anti-tumorigenic and anti-osteoclastogenic effects. Recombinant ADAM17 degraded IFN-Î 3 into small fragments. The addition of ADAM17 to the culture supernatant of stimulated mouse splenocytes decreased IFN-Î 3 concentration. However, ADAM17 inhibition in the stimulated mouse T-cells prevented IFN-Î 3 degradation. ADAM17-expressing human breast cancer cell lines MCF-7 and MDA-MB-453 also degraded recombinant IFN-Î 3, but this was attenuated by ADAM17 inhibition. Degraded IFN-Î 3 lost the functionality including the inhibititory effect on osteoclastogenesis. This is the first study to demonstrate the extracellular proteolytic degradation of IFN-Î 3 by ADAM17. These results suggest that ADAM17-mediated degradation of IFN-Î 3 may block the anti-tumorigenic and anti-osteoclastogenic effects of IFN-Î 3. ADAM17 inhibition may be useful for the treatment of attenuated cancer immune surveillance and/or bone metastases.

Original languageEnglish
Article number32259
JournalScientific reports
Volume6
DOIs
Publication statusPublished - Aug 30 2016

Fingerprint

Disintegrins
Metalloproteases
Interferon-gamma
Neoplasms
Bone and Bones
ADAM17 Protein
Bone Resorption
Osteogenesis
Peptide Hydrolases
Cell Proliferation
Breast Neoplasms
Cytokines
Neoplasm Metastasis
T-Lymphocytes
Cell Line

All Science Journal Classification (ASJC) codes

  • General

Cite this

Kanzaki, H., Shinohara, F., Suzuki, M., Wada, S., Miyamoto, Y., Yamaguchi, Y., ... Nakamura, Y. (2016). A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma. Scientific reports, 6, [32259]. https://doi.org/10.1038/srep32259

A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma. / Kanzaki, Hiroyuki; Shinohara, Fumiaki; Suzuki, Maiko; Wada, Satoshi; Miyamoto, Yutaka; Yamaguchi, Yuuki; Katsumata, Yuta; Makihira, Seicho; Kawai, Toshi; Taubman, Martin A.; Nakamura, Yoshiki.

In: Scientific reports, Vol. 6, 32259, 30.08.2016.

Research output: Contribution to journalArticle

Kanzaki, H, Shinohara, F, Suzuki, M, Wada, S, Miyamoto, Y, Yamaguchi, Y, Katsumata, Y, Makihira, S, Kawai, T, Taubman, MA & Nakamura, Y 2016, 'A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma', Scientific reports, vol. 6, 32259. https://doi.org/10.1038/srep32259
Kanzaki H, Shinohara F, Suzuki M, Wada S, Miyamoto Y, Yamaguchi Y et al. A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma. Scientific reports. 2016 Aug 30;6. 32259. https://doi.org/10.1038/srep32259
Kanzaki, Hiroyuki ; Shinohara, Fumiaki ; Suzuki, Maiko ; Wada, Satoshi ; Miyamoto, Yutaka ; Yamaguchi, Yuuki ; Katsumata, Yuta ; Makihira, Seicho ; Kawai, Toshi ; Taubman, Martin A. ; Nakamura, Yoshiki. / A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma. In: Scientific reports. 2016 ; Vol. 6.
@article{84adf39a69aa434fb8ada7a5a8d77a79,
title = "A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma",
abstract = "Interferon-gamma (IFN-{\^I} 3) is a pleiotropic cytokine that exerts anti-tumor and anti-osteoclastogenic effects. Although transcriptional and post-transcriptional regulation of IFN-{\^I} 3 is well understood, subsequent modifications of secreted IFN-{\^I} 3 are not fully elucidated. Previous research indicates that some cancer cells escape immune surveillance and metastasize into bone tissue by inducing osteoclastic bone resorption. Peptidases of the a-disintegrin and metalloproteinase (ADAM) family are implicated in cancer cell proliferation and tumor progression. We hypothesized that the ADAM enzymes expressed by cancer cells degrades IFN-{\^I} 3 and attenuates IFN-{\^I} 3-mediated anti-tumorigenic and anti-osteoclastogenic effects. Recombinant ADAM17 degraded IFN-{\^I} 3 into small fragments. The addition of ADAM17 to the culture supernatant of stimulated mouse splenocytes decreased IFN-{\^I} 3 concentration. However, ADAM17 inhibition in the stimulated mouse T-cells prevented IFN-{\^I} 3 degradation. ADAM17-expressing human breast cancer cell lines MCF-7 and MDA-MB-453 also degraded recombinant IFN-{\^I} 3, but this was attenuated by ADAM17 inhibition. Degraded IFN-{\^I} 3 lost the functionality including the inhibititory effect on osteoclastogenesis. This is the first study to demonstrate the extracellular proteolytic degradation of IFN-{\^I} 3 by ADAM17. These results suggest that ADAM17-mediated degradation of IFN-{\^I} 3 may block the anti-tumorigenic and anti-osteoclastogenic effects of IFN-{\^I} 3. ADAM17 inhibition may be useful for the treatment of attenuated cancer immune surveillance and/or bone metastases.",
author = "Hiroyuki Kanzaki and Fumiaki Shinohara and Maiko Suzuki and Satoshi Wada and Yutaka Miyamoto and Yuuki Yamaguchi and Yuta Katsumata and Seicho Makihira and Toshi Kawai and Taubman, {Martin A.} and Yoshiki Nakamura",
year = "2016",
month = "8",
day = "30",
doi = "10.1038/srep32259",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma

AU - Kanzaki, Hiroyuki

AU - Shinohara, Fumiaki

AU - Suzuki, Maiko

AU - Wada, Satoshi

AU - Miyamoto, Yutaka

AU - Yamaguchi, Yuuki

AU - Katsumata, Yuta

AU - Makihira, Seicho

AU - Kawai, Toshi

AU - Taubman, Martin A.

AU - Nakamura, Yoshiki

PY - 2016/8/30

Y1 - 2016/8/30

N2 - Interferon-gamma (IFN-Î 3) is a pleiotropic cytokine that exerts anti-tumor and anti-osteoclastogenic effects. Although transcriptional and post-transcriptional regulation of IFN-Î 3 is well understood, subsequent modifications of secreted IFN-Î 3 are not fully elucidated. Previous research indicates that some cancer cells escape immune surveillance and metastasize into bone tissue by inducing osteoclastic bone resorption. Peptidases of the a-disintegrin and metalloproteinase (ADAM) family are implicated in cancer cell proliferation and tumor progression. We hypothesized that the ADAM enzymes expressed by cancer cells degrades IFN-Î 3 and attenuates IFN-Î 3-mediated anti-tumorigenic and anti-osteoclastogenic effects. Recombinant ADAM17 degraded IFN-Î 3 into small fragments. The addition of ADAM17 to the culture supernatant of stimulated mouse splenocytes decreased IFN-Î 3 concentration. However, ADAM17 inhibition in the stimulated mouse T-cells prevented IFN-Î 3 degradation. ADAM17-expressing human breast cancer cell lines MCF-7 and MDA-MB-453 also degraded recombinant IFN-Î 3, but this was attenuated by ADAM17 inhibition. Degraded IFN-Î 3 lost the functionality including the inhibititory effect on osteoclastogenesis. This is the first study to demonstrate the extracellular proteolytic degradation of IFN-Î 3 by ADAM17. These results suggest that ADAM17-mediated degradation of IFN-Î 3 may block the anti-tumorigenic and anti-osteoclastogenic effects of IFN-Î 3. ADAM17 inhibition may be useful for the treatment of attenuated cancer immune surveillance and/or bone metastases.

AB - Interferon-gamma (IFN-Î 3) is a pleiotropic cytokine that exerts anti-tumor and anti-osteoclastogenic effects. Although transcriptional and post-transcriptional regulation of IFN-Î 3 is well understood, subsequent modifications of secreted IFN-Î 3 are not fully elucidated. Previous research indicates that some cancer cells escape immune surveillance and metastasize into bone tissue by inducing osteoclastic bone resorption. Peptidases of the a-disintegrin and metalloproteinase (ADAM) family are implicated in cancer cell proliferation and tumor progression. We hypothesized that the ADAM enzymes expressed by cancer cells degrades IFN-Î 3 and attenuates IFN-Î 3-mediated anti-tumorigenic and anti-osteoclastogenic effects. Recombinant ADAM17 degraded IFN-Î 3 into small fragments. The addition of ADAM17 to the culture supernatant of stimulated mouse splenocytes decreased IFN-Î 3 concentration. However, ADAM17 inhibition in the stimulated mouse T-cells prevented IFN-Î 3 degradation. ADAM17-expressing human breast cancer cell lines MCF-7 and MDA-MB-453 also degraded recombinant IFN-Î 3, but this was attenuated by ADAM17 inhibition. Degraded IFN-Î 3 lost the functionality including the inhibititory effect on osteoclastogenesis. This is the first study to demonstrate the extracellular proteolytic degradation of IFN-Î 3 by ADAM17. These results suggest that ADAM17-mediated degradation of IFN-Î 3 may block the anti-tumorigenic and anti-osteoclastogenic effects of IFN-Î 3. ADAM17 inhibition may be useful for the treatment of attenuated cancer immune surveillance and/or bone metastases.

UR - http://www.scopus.com/inward/record.url?scp=84985943457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985943457&partnerID=8YFLogxK

U2 - 10.1038/srep32259

DO - 10.1038/srep32259

M3 - Article

C2 - 27573075

AN - SCOPUS:84985943457

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 32259

ER -